title: Sleep deprivation and hypothalamic-pituitary-adrenal (HPA) axis activity in depressed patients.
abstract: In the present study we investigated HPA axis activity in depressed patients treated with partial sleep deprivation (PSD) in order to identify endocrinological characteristics related to PSD responsiveness. Thirty-three drug-free patients (14 men, 19 women) suffering from major depression according to DSM-IV criteria were treated with PSD. Response to PSD was defined as a reduction of at least 30% according to the 6-item version of the Hamilton Depression Scale (6-HAMD). Subsequently, the combined dexamethasone-suppression/CRH-stimulation test (DEX/CRH test) was performed. Patients were pretreated with 1.5 mg dexamethasone (DEX) at 23:00 h and challenged with 100 microg corticotropin-releasing hormone (CRH) the following day. Postdexamethasone cortisol concentrations (before CRH administration) served as parameters for the DST status (dexamethasone suppression test). The cortisol stimulation after CRH was used as measurement for the DEX/CRH test status. Of the depressive patients, 54.5% (18 out of 33) responded to PSD. DST suppressors (postdexamethasone cortisol levels < 15 ng/ml) showed a significantly greater reduction in 6-HAMD scores after PSD than DST nonsuppressors. Furthermore, a significant negative correlation between postdexamethasone cortisol levels and reduction in 6-HAMD scores after PSD could be established. However, there was no relationship between the cortisol stimulation following CRH challenge and response to PSD. Although the combined DEX/CRH challenge test is a more sensitive marker for HPA axis dysregulation in depression than the standard DST, the negative feedback of the HPA system reflected by the DST status is apparently more closely associated with response to partial sleep deprivation in major depressive disorder.
authors.affiliation: Department of Psychiatry, Ludwig-Maximilian-University, Nussbaumstr. 7, 80336 Munich, Germany. cornelius.schuele@psy.med.uni-muenchen.de
authors.forename: C
authors.initials: C
authors.lastname: Schüle
authors.forename: T
authors.initials: T
authors.lastname: Baghai
authors.forename: P
authors.initials: P
authors.lastname: Zwanzger
authors.forename: C
authors.initials: C
authors.lastname: Minov
authors.forename: F
authors.initials: F
authors.lastname: Padberg
authors.forename: R
authors.initials: R
authors.lastname: Rupprecht
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000097:blood; D000328:Adult; D000368:Aged; D003346:Corticotropin-Releasing Hormone; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy; D003907:Dexamethasone; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007030:Hypothalamo-Hypophyseal System / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D010555:Personality Inventory; D010913:Pituitary-Adrenal System / Q000503:physiopathology*; D012892:Sleep Deprivation / Q000503:physiopathology*; D016896:Treatment Outcome
chemical_list: D003907:Dexamethasone; D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone; D006854:Hydrocortisone